JP2013530155A5 - - Google Patents

Download PDF

Info

Publication number
JP2013530155A5
JP2013530155A5 JP2013512128A JP2013512128A JP2013530155A5 JP 2013530155 A5 JP2013530155 A5 JP 2013530155A5 JP 2013512128 A JP2013512128 A JP 2013512128A JP 2013512128 A JP2013512128 A JP 2013512128A JP 2013530155 A5 JP2013530155 A5 JP 2013530155A5
Authority
JP
Japan
Prior art keywords
listeria
cancer
attenuated
metabolically active
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013512128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530155A (ja
JP5977737B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/037602 external-priority patent/WO2011149852A1/en
Publication of JP2013530155A publication Critical patent/JP2013530155A/ja
Publication of JP2013530155A5 publication Critical patent/JP2013530155A5/ja
Application granted granted Critical
Publication of JP5977737B2 publication Critical patent/JP5977737B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013512128A 2010-05-23 2011-05-23 癌の補助薬物療法でリステリアを使用する方法および組成物 Expired - Fee Related JP5977737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34744710P 2010-05-23 2010-05-23
US61/347,447 2010-05-23
PCT/US2011/037602 WO2011149852A1 (en) 2010-05-23 2011-05-23 Methods and compositions using listeria for adjuvant treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016074013A Division JP6246252B2 (ja) 2010-05-23 2016-04-01 癌の補助薬物療法でリステリアを使用する方法および組成物

Publications (3)

Publication Number Publication Date
JP2013530155A JP2013530155A (ja) 2013-07-25
JP2013530155A5 true JP2013530155A5 (https=) 2014-07-03
JP5977737B2 JP5977737B2 (ja) 2016-08-24

Family

ID=45004314

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013512128A Expired - Fee Related JP5977737B2 (ja) 2010-05-23 2011-05-23 癌の補助薬物療法でリステリアを使用する方法および組成物
JP2016074013A Expired - Fee Related JP6246252B2 (ja) 2010-05-23 2016-04-01 癌の補助薬物療法でリステリアを使用する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016074013A Expired - Fee Related JP6246252B2 (ja) 2010-05-23 2016-04-01 癌の補助薬物療法でリステリアを使用する方法および組成物

Country Status (6)

Country Link
US (1) US9161974B2 (https=)
EP (1) EP2576791B8 (https=)
JP (2) JP5977737B2 (https=)
CN (1) CN102947452A (https=)
ES (1) ES2613630T3 (https=)
WO (1) WO2011149852A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
SG11201609135VA (en) * 2014-05-02 2016-11-29 Univ Pennsylvania Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
WO2016073866A1 (en) * 2014-11-07 2016-05-12 The Johns Hopkins University Polyfunctional lymphocytes as a biomarker of antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107213458A (zh) * 2017-03-14 2017-09-29 中国人民解放军第三军医大学 一种使用载体组合的新型治疗性疫苗及使用方法
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
WO2019118760A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
CN108714210B (zh) * 2018-08-06 2022-09-30 苏州圣苏新药开发有限公司 重组减毒李斯特菌在制备间皮素高表达癌症治疗性疫苗中的应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CA3218544A1 (en) * 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US20020150588A1 (en) 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
EP1575500A4 (en) * 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
AU2004281834A1 (en) 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CA2613012A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US20070190029A1 (en) * 2005-08-19 2007-08-16 Cerus Corporation Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2007103225A2 (en) * 2006-03-01 2007-09-13 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
WO2008094188A2 (en) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2013530155A5 (https=)
Ai et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Lemay et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
Jager et al. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes?
IN2015DN00376A (https=)
JP2012046524A5 (https=)
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
PH12016500619A1 (en) Dry powder inhaler
MX372883B (es) Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
WO2016030760A3 (en) Treatment of inflammation, respiratory tract infections and cystic fibrosis
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
HK1222134A1 (zh) 治疗人的实体肿瘤的诺氏梭菌
WO2010129339A3 (en) Compositions and methods for enhancing antigen-specific immune responses
MX358680B (es) Usos de inmunoconjugados dirigidos a cd138.
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
MX2021006751A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
WO2010086838A3 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
Jia et al. The future of cancer vaccines against colorectal cancer
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
Dosset et al. Modulation of determinant factors to improve therapeutic combinations with immune checkpoint inhibitors
WO2013096732A3 (en) Methods of treating or preventing viral diseases by blocking interleukin-21